The Journal of Neurosurgery published an article outlining "awake spinal fusion" using the endoscopic transforaminal lumbar interbody fusion technique without general anesthesia.
Biologics
InVivo Therapeutics reported raising net proceeds of $16.5 million in 2018 and implemented significant cost savings measures last year.
Bioventus launched Osteoamp Select Fibers for use with its bone graft substitutes for spine, foot, ankle orthopedic and trauma surgeons.
Using the bone morphogenetic protein rhBMP-2 in the disc space for minimally invasive transforaminal lumbar interbody fusion led to a 97.9 percent fusion rate, according to a study in Clinical Spine Surgery.
The global spinal biologics market is projected to grow at a 3.6 percent compound annual growth rate to reach $2.55 billion by 2024, according to a Market Study Report.
Advertisement
Here are 13 key players in the global non-metal orthopedic biomaterial market, according to a Markets N Research report.
AlloSource enrolled the first patient in a study of its ProChondrix CR for articular cartilage defect repair.
The FDA cleared Atreon Orthopedics' Rotium Bioresorbable Wick for healing rotator cuff injuries.
Barbara A. Binzak Blumenfeld, PhD, is a shareholder at Buchanan Ingersoll & Rooney. She focuses her practice on the regulation of biologic research, and recently spoke with Becker’s Spine Review about where regenerative medicine is headed.
Regenerative medicine company CollPlant renewed its exclusive distribution agreement with Arthrex for its soft tissue repair product Vergenix STR.